Table 2:

Univariable (UVA) and multivariable (MVA) Cox regression analysis to identify predictors for worse OS in the IO cohort with outcomes data available (2015 diagnoses only). Two MVA models were tested, including a “contingent” model developed based on covariates found to be significant on UVA and an “a priori” model based on prespecified covariates. Total mortality events: n=75.

	UVA		“Contingent” MVA		“A priori” MVA
	HR (95% CI)	p-value*	HR (95% CI)	p-value*	HR (95% CI)	p-value*
CN performed	0.23 (0.15–0.37)	<0.001	0.24 (0.14–0.41)	<0.001	0.22 (0.11–0.42)	<0.001
Age	1.02 (1.00–1.04)	0.097			1.00 (0.97–1.04)	0.785
Male sex	0.99 (0.60–1.62)	0.955
Race -White -Black -Hispanic -Asian/Other	Ref. 1.05 (0.38–2.90) 1.15 (0.53–2.51) 0.69 (0.17–2.82)	Ref. 0.925 0.731 0.605
Charlson-Deyo comorbidity score −0 −1 −2	Ref. 1.62 (0.94–2.79) 0.54 (0.13–2.22)	Ref. 0.082 0.393
Sarcomatoid features	0.71 (0.18–2.91)	0.637
Primary tumor size	1.00 (0.99–1.00)	0.199
Locally advanced cT stage (cT3–4)	0.92 (0.54–1.57)	0.760			0.86 (0.43–1.71)	0.661
cN1 stage	1.23 (0.73–2.06)	0.432			1.17 (0.60–2.28)	0.642
Presence of bone metastases	1.30 (0.77–2.21)	0.322
Presence of brain metastases	1.76 (0.83–3.73)	0.142
Presence of liver metastases	2.68 (1.45–4.93)	0.002
Presence of lung metastases	0.95 (0.53–1.70)	0.855
Presence of bone, liver, or brain metastases	2.01 (1.14–3.52)	0.015	1.62 (0.91–2.87)	0.098	1.20 (0.60–2.38)	0.607
Number of known metastatic sites −1 −2 −3 −4 -No bone, brain, liver, or lung involvement	1.16 (0.35–3.84) 2.54 (0.76–8.47) 1.70 (0.38–7.60) 7.94 (0.81–77.88) Ref.	0.813 0.129 0.489 0.075 Ref.

HR: hazard ratio; CI: confidence interval; UVA: univariable analysis; MVA: multivariable analysis

^*P<0.05 indicates significance